HOME >> BIOLOGY >> NEWS
Johns Hopkins gene hunters pinpoint new cancer gene target

Scientists at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute have found mutations in a gene linked to the progression of colon and other cancers. The research findings, published online in the March 11 issue of Science, may lead to new therapies and diagnostic tests that target this gene.

The gene in which the mutations have been found, called PIK3CA, is part of a family of genes encoding lipid kinases, enzymes that modify fatty molecules and direct cells to grow, change shape and move. Although scientists have been studying the biochemical properties of this family of genes for more than a decade, until now, no study revealed that they were mutated in cancer.

Kinases have been the focus of recent drug development strategies, with some kinase-inhibiting compounds, such as Gleevec and Herceptin, already being used clinically to inhibit tumor growth.

"These findings open the door to developing specific therapies that may prove useful for the treatment of cancers with mutations in PIK3CA," says Victor Velculescu, M.D., Ph.D., assistant professor of oncology and senior author of the research.

In their current experiments, the scientists sequenced the molecular code of the genes in this lipid kinase family and found mistakes in the nucleotides, or DNA building blocks, in one particular gene, called PIK3CA. Each mistake is a result of one nucleotide being switched for another. PIK3CA mutations were found in 32 percent of colon cancer samples (74/234), as well as 27 percent (4/15) of glioblastomas, 25 percent (3/12) of gastric cancers, 8 percent (1/12) breast cancers and 4 percent (1/24) of lung cancers. By studying 76 additional premalignant colon tumors, the scientists found that PIK3CA mutations may occur at or near the time a tumor is about to invade other tissues.

The investigators demonstrated that the mutations increase PIK3CA kinase activity, which can start a cascade of cellular events
'"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
11-Mar-2004


Page: 1 2

Related biology news :

1. Yale professor receives Johnson & Johnson Focused Giving award
2. Marian Johnson-Thompson wins 2004 Alice C. Evans Award
3. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
4. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
5. Johns Hopkins receives $24 million from Donald W. Reynolds Foundation to study sudden cardiac death
6. Johns Hopkins researchers devise methods to evaluate disaster drills
7. Johns Hopkins scientists create forgetful mouse
8. A bed of microneedles: Johns Hopkins scientists gadget measures muscle cell force
9. Wake Forest-Johns Hopkins team discovers prostate cancer gene
10. The next generation of scientists recognized at Johns Hopkins
11. Johns Hopkins scientists find brains nose plug

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2020)... ... March 09, 2020 , ... ... last year, as enterprises sought to achieve competitive advantage by transforming their ... of all transformation efforts delivered the intended consequences. , Application transformation refers ...
(Date:3/5/2020)... (PRWEB) , ... March 05, 2020 , ... ... preparation and epigenetics research, and MGI Tech (MGI), a subsidiary of global genomics ... preparation product line in the United States, Europe and Asia Pacific. , ...
(Date:3/4/2020)... ... March 04, 2020 , ... ... and services, announced it has been nominated as a finalist in the category ... This nomination comes as VGXI expedites manufacturing of a DNA vaccine against the ...
Breaking Biology News(10 mins):
(Date:3/27/2020)... ... March 26, 2020 , ... iFirst Medical Technologies, Inc., a ... COVID-19 nasal swab test. , "COVID-19 poses a grave danger to public health here ... at iFirst are compelled to act. Broad-based testing and on-the-spot results promise to slow ...
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a global leader ... announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing ... run on ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. ...
(Date:3/3/2020)... ... March 03, 2020 , ... ... pharmaceutical, biotech and medical device industries, was recognized by INC. 5,000 on an ... annual lists to note industry leaders greatly impacting their spheres of influence and ...
(Date:2/21/2020)... ... , ... In a free session on Tuesday, March 10, 2020 ... Dilworth, BS, MS, Vice President Rare, Orphan and Pediatric Diseases, and Rachael Young, Associate ... support patients, sites and sponsors. , When planning a rare disease clinical trial, drug ...
Breaking Biology Technology:
Cached News: